pharmaphorum

MARCH 15, 2022

The shift to virtual alone has already had a profound impact on all conference stakeholders: medical societies themselves, doctors, patients, commercial partners, and professional conference organisers (PCOs). Doctors want a choice. These order of magnitude increases were also reflected at national levels. yes; and 15.7%

Doctors 106

Doctors Doctor Cardiology Allergies 106

Velocity Clinical Research

JANUARY 3, 2024

The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. KO-MED has been the leading multi-site network in Poland since 2020, having enrolled over 9,000 patients into clinical research.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Trials 52

The Pharma Data

NOVEMBER 4, 2020

Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. Research and development (R&D) expense for the three and nine months ended September 30, 2020 were $10.2

Sales 40

Sales Production Cardiology Marketing 40